A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

~54 mi. (Sainte-Foy, Canada, +126 more cities)

Research Site

ER Positive, +2 more biomarkers

Breast Carcinoma

datopotamab deruxtecan

targeted therapy

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

~55 mi. (Lévis, Canada, +234 more cities)

Research Site

Non-Small Cell Lung Carcinoma

carboplatin, +5 more drugs

chemotherapy, +1 more type

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

~55 mi. (Lévis, Canada, +221 more cities)

Research Site

IRF4 Expression, +1 more biomarker

Diffuse Large B-Cell Lymphoma

acalabrutinib, +5 more drugs

chemotherapy, +3 more types

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

~55 mi. (Lévis, Canada, +189 more cities)

CISSS-CA (Centre Integre de sante et de services sociaux de Chaudiere-Appalache) /ID# 222433

del(11)(q10), +27 more biomarkers

Myelofibrosis Transformation in Essential Thrombocythemia, +2 more conditions

navitoclax, +1 more drug

targeted therapy

A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

~55 mi. (Lévis, Canada, +156 more cities)

CISSS-CA (Centre Integre de sante et de services sociaux de Chaudiere-Appalache) /ID# 218887

IGH-CCND1 Fusion, +1 more biomarker

Multiple Myeloma

dexamethasone, +1 more drug

chemotherapy, +1 more type

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

~56 mi. (Québec, Canada, +89 more cities)

Hopital Du Saint-Sacrement ( Site 0109)

ER Positive, +2 more biomarkers

Breast Carcinoma

capecitabine, +4 more drugs

chemotherapy, +1 more type

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

~56 mi. (Québec, Canada, +744 more cities)

CHU de Quebec-Hopital du Saint-Sacrement (HSS)

Breast Carcinoma

axillary lymph node dissection, +1 more drug

radiation therapy, +1 more type

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

~56 mi. (Québec, Canada, +269 more cities)

CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)

ER Positive, +1 more biomarker

Invasive Breast Carcinoma

radiation therapy, +1 more drug

radiation therapy

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

~56 mi. (Québec, Canada, +454 more cities)

CHA Hopital L'Enfant-Jesus

Classical Hodgkin Lymphoma

brentuximab vedotin, +7 more drugs

chemotherapy, +3 more types

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

~56 mi. (Québec, Canada, +262 more cities)

Hopital du Saint Sacrement

ER Positive, +1 more biomarker

Breast Adenocarcinoma

giredestrant, +2 more drugs

hormone therapy, +1 more type

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

~56 mi. (Québec, Canada, +356 more cities)

CHU de Quebec - Hopital du Saint-Sacrement

HER2 Positive

Invasive Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

~56 mi. (Québec, Canada, +664 more cities)

CHA Hopital L'Enfant-Jesus

PD-L1 High Expression (TPS >= 1%), +1 more biomarker

Non-Small Cell Lung Carcinoma

carboplatin, +2 more drugs

chemotherapy, +1 more type